Kathleen Tregoning is of Cerevel Therapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of CERE, which is worth approximately $0. The most recent transaction as insider was on Aug 01, 2024, when has been sold 10,666 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
100.0% 12M change
Total Value Held $0

Kathleen Tregoning Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 01 2024
SELL
Sale (or disposition) back to the issuer
-
10,666 Reduced 100.0%
0 Common Stock
Dec 26 2023
BUY
Exercise of conversion of derivative security
$31,657 $10.05 p/Share
3,150 Added 22.8%
10,666 Common Stock
Dec 20 2023
SELL
Open market or private sale
$260,448 $41.42 p/Share
6,288 Reduced 45.55%
7,516 Common Stock
Dec 19 2023
BUY
Exercise of conversion of derivative security
-
13,804 Added 50.0%
13,804 Common Stock

Also insider at

SPRO
Spero Therapeutics, Inc. Healthcare
KT

Kathleen Tregoning

Cambridge, MA

Track Institutional and Insider Activities on CERE

Follow Cerevel Therapeutics Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERE shares.

Notify only if

Insider Trading

Get notified when an Cerevel Therapeutics Holdings, Inc. insider buys or sells CERE shares.

Notify only if

News

Receive news related to Cerevel Therapeutics Holdings, Inc.

Track Activities on CERE